Pérez-López Faustino R, Bueno-Notivol Juan, Hernandez Adrian V, Vieira-Baptista Pedro, Preti Mario, Bornstein Jacob
Department of Obstetrics and Gynecology, University of Zaragoza Faculty of Medicine , Zaragoza , Spain.
Red de Investigacion de Ginecologia, Obstetricia y Reproduccion, Instituto Aragonés de Investigaciones Sanitarias , Zaragoza , Spain.
Eur J Contracept Reprod Health Care. 2019 Oct;24(5):337-346. doi: 10.1080/13625187.2019.1643835. Epub 2019 Jul 31.
To quantify the effects of available treatments of vestibulodynia. Systematic review of randomised controlled trials (RCTs) in six search engines until December 2018, comparing any intervention vs. placebo or sham in women with vestibulodynia. Primary outcome was dyspareunia assessed with visual analogue (VAS) or numeric rating (NRS) scales. Secondary outcomes were daily vestibular symptoms (DVS), McGill Pain Questionnaire (MPQ) and Index of Sexual Satisfaction (ISS). Effects were described as mean differences (MDs) with their 95% confidence intervals (CIs). Traditional and frequentist network meta-analyses (NMA) were performed using random effect models. Four RCTs ( = 275) were included evaluating vaginal cream of conjugated oestrogens, oral desipramine with or without topical lidocaine, topical lidocaine, laser therapy and transcranial direct current. In traditional MA, interventions did not reduce dyspareunia (MD = 0.08; 95%CI = -0.49 to 0.64), DVS (MD = -0.04; 95%CI = -0.31 to 0.24; 4 interventions), or MPQ (MD = -0.17; 95%CI = -2.16 to 1.81; 4 interventions). ISS was significantly improved (MD = -5.14; 95%CI = -9.52 to -0.75). In NMA, oral desipramine with or without lidocaine significantly improved ISS vs. other treatments. Several existing interventions were not associated with improvements in vestibulodynia. There only was improvement of sexual function with oral desipramine with or without lidocaine.
为了量化现有的前庭痛治疗方法的效果。截至2018年12月,在六个搜索引擎中对随机对照试验(RCT)进行系统评价,比较前庭痛女性中任何干预措施与安慰剂或假治疗的效果。主要结局是用视觉模拟量表(VAS)或数字评定量表(NRS)评估的性交疼痛。次要结局是每日前庭症状(DVS)、麦吉尔疼痛问卷(MPQ)和性满意度指数(ISS)。效应以平均差(MD)及其95%置信区间(CI)表示。使用随机效应模型进行传统的和频率学派的网状Meta分析(NMA)。纳入了四项RCT(n = 275),评估结合雌激素阴道乳膏、口服地昔帕明(加或不加局部利多卡因)、局部利多卡因、激光治疗和经颅直流电刺激。在传统的Meta分析中,干预措施并未减轻性交疼痛(MD = 0.08;95%CI = -0.49至0.64)、DVS(MD = -0.04;95%CI = -0.31至0.24;4项干预措施)或MPQ(MD = -0.17;95%CI = -2.16至1.81;4项干预措施)。ISS有显著改善(MD = -5.14;95%CI = -9.52至-0.75)。在NMA中,加或不加利多卡因的口服地昔帕明与其他治疗相比,显著改善了ISS。几种现有的干预措施与前庭痛的改善无关。只有加或不加利多卡因的口服地昔帕明改善了性功能。